|

Studying the Role of Circulating Tumor Cell Clusters in Patients With High-risk Early Breast Cancer, Study GALIA

RECRUITINGN/ASponsored by Institute of Oncology Ljubljana
Actively Recruiting
PhaseN/A
SponsorInstitute of Oncology Ljubljana
Started2024-02-07
Est. completion2028-12-31
Eligibility
Age18 Years+
SexFEMALE
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT07418125

Summary

CTCs, CTC clusters, and ctDNA may predict treatment response and survival in high-risk breast cancer, including IBC.

Eligibility

Age: 18 Years+Sex: FEMALEHealthy volunteers accepted
Inclusion Criteria:

* Patients with inflammatory breast cancer, regardless of cancer subtype (stage IIID)
* Patients with non-inflammatory breast cancer: triple-negative and HER2+ subtypes, from stage IIB to IIIA-C
* Adequate health status for neoadjuvant systemic treatment

Exclusion Criteria:

* Inflammatory breast cancer stage IV
* Luminal A, luminal B subtypes of non-inflammatory breast cancer
* Stages I-IIA breast cancer
* Inability to understand or communicate in Slovenian
* Inability to follow protocol instructions
* Inappropriate health status for chemotherapy treatment
* Primary treatment with surgery

Conditions2

Breast CancerCancer

Browse More Trials

Cancer trialsBreast Cancer trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.